Eidos Therapeutics (Eidos Therapeutics) Market Cap : $4,750.66 Mil (As of Apr. 25, 2024)

View and export this data going back to 2018. Start your Free Trial

What is Eidos Therapeutics Market Cap?

Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Eidos Therapeutics's share price for the quarter that ended in Sep. 2020 was $50.53. Eidos Therapeutics's Shares Outstanding (EOP) for the quarter that ended in Sep. 2020 was 38.59 Mil. Therefore, Eidos Therapeutics's market cap for the quarter that ended in Sep. 2020 was $1,950.06 Mil.

Eidos Therapeutics's quarterly market cap declined from Mar. 2020 ($1,887.53 Mil) to Jun. 2020 ($1,838.20 Mil) but then increased from Jun. 2020 ($1,838.20 Mil) to Sep. 2020 ($1,950.06 Mil).

Eidos Therapeutics's annual market cap increased from Dec. 2017 ($0.00 Mil) to Dec. 2018 ($505.82 Mil) and increased from Dec. 2018 ($505.82 Mil) to Dec. 2019 ($2,183.16 Mil).

Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Eidos Therapeutics's Enterprise Value for Today is $4,624.80 Mil.

Eidos Therapeutics Market Cap Historical Data

The historical data trend for Eidos Therapeutics's Market Cap can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eidos Therapeutics Market Cap Chart

Eidos Therapeutics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Market Cap

505.82

2,183.16

Eidos Therapeutics Quarterly Data
	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20
Market Cap	Get a 7-Day Free Trial											1,348.75	2,183.16	1,887.53	1,838.20	1,950.06

Competitive Comparison of Eidos Therapeutics's Market Cap

For the Biotechnology subindustry, Eidos Therapeutics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Eidos Therapeutics's Market Cap Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Eidos Therapeutics's Market Cap distribution charts can be found below:

* The bar in red indicates where Eidos Therapeutics's Market Cap falls into.

Eidos Therapeutics Market Cap Calculation

Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.

Eidos Therapeutics's Market Cap for the fiscal year that ended in Dec. 2019 is calculated as

Market Cap (A: Dec. 2019 )	=	Share Price (A: Dec. 2019 )	*	Shares Outstanding (EOP) (A: Dec. 2019 )
	=	$57.39	*	38.0407
	=	$2,183.16

Eidos Therapeutics's Market Cap for the quarter that ended in Sep. 2020 is calculated as

Market Cap (Q: Sep. 2020 )	=	Share Price (Q: Sep. 2020 )	*	Shares Outstanding (EOP) (Q: Sep. 2020 )
	=	$50.53	*	38.5922
	=	$1,950.06

Eidos Therapeutics (NAS:EIDX) Market Cap Explanation

Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.

Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.

Eidos Therapeutics Market Cap Related Terms

Thank you for viewing the detailed overview of Eidos Therapeutics's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.

Eidos Therapeutics (Eidos Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Eidos Therapeutics Inc (NAS:EIDX) » Definitions » Market Cap

Comparable Companies

Traded in Other Exchanges

N/A

Address

101 Montgomery Street, Suite 2000, San Francisco, CA, USA, 94104

Website

https://www.eidostx.com

Eidos Therapeutics Inc is a clinical stage biopharmaceutical company focused on addressing the large and growing unmet need in diseases caused by transthyretin, or TTR, amyloidosis, or ATTR. TTR is a protein that occurs naturally in the form of a tetramer and performs multiple beneficial roles, including the transport of essential hormones and vitamins. The company's product candidate, AG10, is an orally-administered small molecule designed to potently stabilize tetrameric TTR.

Executives

Uma Sinha	director, officer: Chief Scientific Officer	C/O EIDOS THERAPEUTICS, INC., 101 MONTGOMERY STREET, SUITE 2550, SAN FRANCISCO CA 94101
Franco Valle	officer: Senior Vice President, Finance	999 SKYWAY ROAD, SUITE 150, SAN CARLOS CA 94070
Cameron Turtle	officer: Chief Business Officer	C/O EIDOS THERAPEUTICS, INC., 101 MONTGOMERY STREET, SUITE 2550, SAN FRANCISCO CA 94104
Jonathan C Fox	officer: See Remarks	C/O MYOKARDIA, INC., 333 ALLERTON AVENUE, SOUTH SAN FRANCISCO CA 94080
Suzanne Sawochka Hooper	director	C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2
Douglas Rohlen	director	3600 HOLLY LANE NORTH, SUITE 40 PLYMOUTH MN 55447
Eric Aguiar	director	888 7TH AVENUE, 12TH FLOOR, NEW YORK NY 10106
Rajeev M. Shah	director	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Ali J. Satvat	director, 10 percent owner	C/O KOHLBERG KRAVIS ROBERTS & CO., 2800 SAND HILL ROAD, SUITE 200, MENLO PARK CA 94025
William Lis	director	PORTOLA PHARMACEUTICALS, INC., 270 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Christine Siu	officer: CFO and Secretary	C/O EIDOS THERAPEUTICS, INC., 101 MONTGOMERY STREET, SUITE 2550, SAN FRANCISCO CA 94101
Bridgebio Pharma, Inc.	10 percent owner	421 KIPLING STREET PALO ALTO CA 94301
Neil Kumar	director, 10 percent owner, officer: Chief Executive Officer	C/O BRIDGEBIO PHARMA, INC., 3160 PORTER DR, STE 250, PALO ALTO CA 94304
Hoyoung Huh	director	C/O NEKTAR THERAPEUTICS, 201 INDUSTRIAL ROAD, SAN CARLOS CA 94070
Peter Kolchinsky	10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116